Astrazeneca (AZN) EV to FCF (2009 - 2026)

Astrazeneca has reported EV to FCF for 18 years, with the latest figure at 79.58 in Q2 2026.

• On a quarterly basis, EV to FCF rose 53.9% year-over-year to 79.58 in Q2 2026; TTM through Jun 2026 was 17.25, a 28.71% increase from a year earlier, with the FY2025 full-year figure at 16.04, up 11.93% from the prior year.
• EV to FCF was 79.58 for Q2 2026 at Astrazeneca, up from 76.24 in the prior quarter.
• The five-year high for EV to FCF was 133.13 in Q2 2022, with the low at 24.9 in Q4 2023.
• Average EV to FCF over 5 years is 65.68, with a median of 61.95 recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: EV to FCF sank 72.49% in 2022, then soared 119.45% in 2024.
• Over 5 years, EV to FCF stood at 27.51 in 2022, then declined by 9.5% to 24.9 in 2023, then jumped by 119.45% to 54.64 in 2024, then soared by 51.06% to 82.54 in 2025, then decreased by 3.59% to 79.58 in 2026.
• The last three EV to FCF figures came in at 79.58 (Q2 2026), 76.24 (Q1 2026), and 82.54 (Q4 2025), per Business Quant data.